ERG would like to congratulate BioXcel Therapeutics for the positive topline results from their post-marketing requirement study of IGALMI™ (dexmedetomidine) sublingual film. This study targeted agitation associated with bipolar disorder and schizophrenia. The team at BioXcel team should be commended for their relentless pursuit of transformative treatments in neuroscience. This achievement is a beacon of hope for patients and a step forward in mental health symptom reduction.   Evolution Research Group was honored to be a part of this important study. We remain steadfast in our mission to improve patient outcomes and enhance the quality of life for those affected by schizophrenia and bipolar disorder.